Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
MS&AD Insurance, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 7%, Exceeds Full-Year Plan
8725 MS&AD Insurance Group Holdings, Inc. 【J-GAAP】
Earnings ReportMS&AD Insurance Group Holdings, Inc. <8725> [TSE Prime] announced its financial results after the market closed on February 13th (15:35). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2026 (April to December) increased 7.5% from the same period last year, reaching 886 billion yen. Progress toward the full-year plan of 834 billion yen is 106.3%, already exceeding the target and also exceeding the five-year average of 81.4%.
Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit/loss for the January to March period (4Q) is expected to turn into a loss of 52.4 billion yen (compared to a profit of 104 billion yen in the same period last year). However, if the fourth-quarter performance remains at the same level as the first three quarters, the full-year plan may be increased.
In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit grew 20.1% from the same period last year, reaching 233 billion yen.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Dec, 2023 | 4,947,791 | ー | 386,579 | 281,596 | 176.5 | 92.8 | Feb 14, 2024 | J-GAAP |
| Apr - Dec, 2024 | 5,229,739 | ー | 824,864 | 626,067 | 400.2 | 88.8 | Feb 14, 2025 | J-GAAP |
| Apr - Dec, 2025 | 5,905,259 | ー | 886,447 | 657,102 | 439.0 | 106.3 | Feb 13, 2026 | J-GAAP |
| YoY | +12.9% | - | +7.5% | +5.0% | +9.7% |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 3,213,006 | ー | 298,187 | 232,670 | 149.9 | 72.50 | May 20, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | ー | ー | 180,649 | 98,326 | 67.1 | 77.50 | Nov 19, 2025 | J-GAAP |
| YoY | - | - | -39.4% | -57.7% | -55.3% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 6,572,889 | ー | 416,440 | 369,266 | 231.8 | 90 | May 20, 2024 | J-GAAP |
| Mar, 2025 | 6,660,813 | ー | 928,989 | 691,657 | 445.5 | 145 | May 20, 2025 | J-GAAP |
| Mar, 2026 Guidance | ー | ー | 834,000 | 590,000 | 402.4 | 155 | Nov 19, 2025 | J-GAAP |
| YoY | - | - | -10.2% | -14.7% | -9.7% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 1,781,932 | ー | 194,062 | 167,080 | 106.8 | 0.0 | Feb 14, 2025 | J-GAAP |
| Jan - Mar, 2025 | 1,431,074 | ー | 104,125 | 65,590 | 42.3 | 0.0 | May 20, 2025 | J-GAAP |
| Apr - Jun, 2025 | 2,020,318 | ー | 284,841 | 222,787 | 147.4 | 0.0 | Aug 8, 2025 | J-GAAP |
| Jul - Sep, 2025 | 2,091,198 | ー | 368,510 | 268,887 | 178.8 | 0.0 | Nov 19, 2025 | J-GAAP |
| Oct - Dec, 2025 | 1,793,743 | ー | 233,096 | 165,428 | 110.5 | 0.0 | Feb 13, 2026 | J-GAAP |
| YoY | +0.7% | - | +20.1% | -1.0% | +3.5% |
Related Articles
PARIS MIKI, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 15%, Exceeds Full-Year Plan
LUCKLAND, 3% Increase in Ordinary Profit, Update Record High for Second Consecutive Term, Dividend Raised by 20 Yen
Delta-Fly Pharma, Apr-Dec (Cumulative 3Q) Net Income Loss Narrows, Oct-Dec Net Income Loss Widens
Future Innovation Group, 21% Increase in Ordinary Profit, Record High for The First Time in Four Years
TAIKO PHARMA, Last Fiscal Year's Ordinary Profit Exceeds Expectations, 8% Increase in The Current Fiscal Year, Resuming Dividends at 3.3 Yen for the First Time in five terms., This Fiscal Year to Increase Dividend by 0.2 Yen
Neural Group, Last Fiscal Year's Ordinary Profit Turns to Loss, Current period performance is undisclosed.
BrightPath Biotherapeutics, Apr-Dec (Cumulative 3Q) Net Income Loss Widens, Oct-Dec Net Income Loss Widens
VELTRA, 3.7 times Increase in Ordinary Profit for The Current Fiscal Year
Dynamic Map, Apr-Dec (Cumulative 3Q) Ordinary Profit Loss Widens, Oct-Dec Ordinary Profit Loss Widens
LIFE CREATE, Ordinary Profit Forecast for the Fiscal Year Revised Downward to an Unexpected 41% Decrease